FDA
-
-
-
-
-
-
-
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
-
-
-
-
-
-
-
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
-
-
-
-
-
-
-
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
-
-
-
-
-
-
-
Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop
-
-
-
-
-
-
-
Rocket Pharmaceuticals receives FDA RMAT designation for heart gene therapy
-
-
-
-
-
-
-
Faruqi & Faruqi Notifies Rocket Pharmaceuticals Investors of a Class Action Lawsuit and Upcoming Deadline - RCKT
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

